Article

Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient <i>In Vivo</i> Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted <sup>177</sup> Lu-DOTATATE

2022-04-26

Abstract excerpt

<h4>Purpose</h4> The goal of this study was to test whether histone deacetylase inhibitors (HDACis) restore somatostatin receptor type 2 (SSTR2) expression in models of high-grade pancreatic neuroendocrine tumors (PNETs), thereby facilitating effective treatment with 177 Lu-DOTATATE therapy. <h4>Methods</h4> To assess tumor grade correlation with SSTR2 expression, we assessed human SSTR2 promoter methylation a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dda532da-ebfa-568f-b6e0-6c1ae068e292
DOI: 10.1101/2022.04.25.489401

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient <i>In Vivo</i> Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted <sup>177</sup> Lu-DOTATATEDOI 10.1101/2022.04.25.489401Read

Multiple Epigenetic Mechanisms Functionally Cooperate to Silence Expression of Somatostatin Receptor Type 2 in Pancreatic Neuroendocrine TumorsSemantic proximity Read

A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing-tumor as a potential target of peptide receptor imaging and therapySemantic proximity Read

Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapySemantic proximity Read

Somatostatin Receptor Based Imaging and Radionuclide TherapySemantic proximity Read

Targeting HDACs in Pancreatic Neuroendocrine Tumor ModelsSemantic proximity Read

Somatostatin Receptor 2 Overexpression in Hepatocellular Carcinoma: Implications for Cancer Biology and Theranostic ApplicationsSemantic proximity Read

Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [177Lu]Lu-DOTATATE therapySemantic proximity Read

Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted TherapySemantic proximity Read

Nothing but NET: A review of norepinephrine transporter expression and efficacy of<sup>131</sup>I‐mIBG therapySemantic proximity Read

Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.Semantic proximity Read

Epigenetic regulation of SST2 expression in small intestinal neuroendocrine tumorsSemantic proximity Read

SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicitySemantic proximity Read